News
First dose completed in phase 1 cannabinoid study
Oxford Cannabinoid Technologies Holdings (OCTP) has announced that the first-in-human dose of its drug candidate, OCT461201, has been successfully administered.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Oxford Cannabinoid Technologies Holdings (OCTP) has announced that the first-in-human dose of its drug candidate, OCT461201, has been successfully administered.